1 års afkast (CAGR)
-14.15%
Bavarian Nordic Exchange (CO, DKK)
BAVA.CO
201.40
+1.00 (+0.50%)
HealthcareBiotechnology
Loading...
3 års afkast (CAGR)
11.65%
5 års afkast (CAGR)
-10.64%
10 års afkast (CAGR)
2.98%
Objective Corporation aktieanalyse – stat inden for stat
Læs mereMarkedsværdi
15.25B
Pris/omsætning
2.42
Ent værdi
15.98B
Pris/bog
1.15
Udbytte afkast
0.00%
Vekst år
-
Udbyttevækst
-
FCF-udbetaling
0.00%
Efterfølgende P/E
9.88
PEG
-
Fremtidig P/E
19.14
EPS-vekst
27.98%
Oplysninger om aktier
Hvad er en børs? Drift, aktører, eksempler
Læs mereAktiediagram
Loading...
Aktiekurs-data
| Åbning | 200.20 |
| Daglig høj | 202.60 |
| Daglig lav | 200.20 |
| Daglig volumen | 87K |
| Højeste gennem alle tider | 401.70 |
| 1 års analytiker estimat | 276.25 |
| Beta | 0.96 |
| EPS (TTM) | 20.31 |
| Udbytte pr. aktie | 0.00 |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 12 Mar 2026 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| BAVA.CO | S&P500 | |
| Nuværende prisfald fra top notering | -49.86% | -3.06% |
| Højeste prisfald | -91.83% | -56.47% |
| Højeste efterår dato | 30 Sep 2002 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -48.27% | -10.68% |
| Gennemsnitlig tid til nyt højdepunkt | 100 days | 12 days |
| Maks. tid til nyt højdepunkt | 1935 days | 1805 days |
Nyheder
COPENHAGEN, Denmark, September 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase...
21. september 2026
COPENHAGEN, Denmark, September 17, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Tarja Stenvall has been appointed President and Chief Executive Officer, effective October 15, 2026, succ...
17. september 2026
COPENHAGEN, Denmark, September 4, 2026 – Bavarian Nordic A/S (OMX: BAVA) has received information about the following transactions of the company’s shares/related securities by persons holding manager...
4. september 2026
COPENHAGEN, Denmark, September 4, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 285,900 as a consequence of employees’ exe...
4. september 2026
COPENHAGEN, Denmark, September 1, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the new share buy-back program announced on August 21, under which the Company intends to r...
1. september 2026
Bavarian Nordic stock has delivered a solid 36.1% return over the past three years, while a fresh intrinsic value estimate using a Discounted Cash Flow (DCF) approach indicates the shares trade at a s...
26. august 2026
Bavarian Nordic AS (BVNKF) raises FY2026 revenue and EBITDA guidance on robust Travel Health and Public Preparedness performance, while navigating Chikungunya headwinds and advancing its pipeline.
21. august 2026
COPENHAGEN, Denmark, August 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the second quarter and first half of 2026 and released it...
21. august 2026
Guidance upgrade reflects upper end of previous guided revenue range and an improved EBITDA margin COPENHAGEN, Denmark, August 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an upgrade of ...
21. august 2026
MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virusApproval further strengthens MVA-BN’s position in su...
7. august 2026